These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21262425)

  • 41. Prophylaxis of thrombosis with low-molecular-weight heparin (LMWH).
    Holzheimer RG
    Eur J Med Res; 2004 Mar; 9(3):150-70. PubMed ID: 15096326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recurrent life-threatening deep tissue hematomas after switching to generic enoxaparin: a report and perspective on the approval process for biological compounds.
    Kaffenberger BH; Bekaii-Saab T
    Clin Appl Thromb Hemost; 2012; 18(1):104-6. PubMed ID: 21873360
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevention of venous thromboembolism.
    Pini M; Spyropoulos AC
    Semin Thromb Hemost; 2006 Nov; 32(8):755-66. PubMed ID: 17171588
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Low molecular weight heparin].
    Pini M
    Recenti Prog Med; 1997 Dec; 88(12):594-602. PubMed ID: 9522605
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SASAT (South Asian Society on Atherosclerosis & Thrombosis) proposal for regulatory guidelines for generic low-molecular weight heparins (LMWHs).
    Kalodiki E; Leong W;
    Clin Appl Thromb Hemost; 2009 Feb; 15(1):8-11. PubMed ID: 19117962
    [No Abstract]   [Full Text] [Related]  

  • 46. Should low-molecular-weight heparins replace unfractionated heparin as the agent of choice for adults with deep venous thrombosis?
    Brewer D
    J Fam Pract; 1998 Sep; 47(3):185-92. PubMed ID: 9752370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
    Huse DM; Cummins G; Taylor DC; Russell MW
    Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Generic forms of low-molecular-weight heparins: some practical considerations.
    Leong W; Hoppensteadt DA
    Clin Appl Thromb Hemost; 2003 Oct; 9(4):293-7. PubMed ID: 14653438
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care?
    Burris HA
    Semin Oncol; 2006 Apr; 33(2 Suppl 4):S3-16; quiz S41-2. PubMed ID: 16638456
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biosimilars of low molecular weight heparins: Relevant background information for your drug formulary.
    Brouwers JRBJ; Roeters van Lennep JE; Beinema MJ
    Br J Clin Pharmacol; 2019 Nov; 85(11):2479-2486. PubMed ID: 31378961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antithrombotics and anticoagulants in coronary syndromes and stroke.
    Turpie AG
    Semin Thromb Hemost; 2000; 26 Suppl 1():79-83. PubMed ID: 11011811
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thromboelastographic evaluation of blood coagulation in the presence of branded and generic enoxaparins.
    Walenga JM; Jeske WP; Escalante V; Hoppensteadt D; Fareed J; Bakhos M
    Int Angiol; 2012 Dec; 31(6):517-25. PubMed ID: 23222929
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low molecular weight heparins: differences and similarities in approved preparations in the United States.
    Bick RL; Fareed J
    Clin Appl Thromb Hemost; 1999 Oct; 5 Suppl 1():S63-6. PubMed ID: 10726038
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low-molecular-weight heparins in thrombosis and cancer: emerging links.
    Mousa SA
    Cardiovasc Drug Rev; 2004; 22(2):121-34. PubMed ID: 15179449
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low-molecular-weight heparin biosimilars: potential implications for clinical practice. Australian Low-Molecular-Weight Heparin Biosimilar Working Group (ALBW).
    Nandurkar H; Chong B; Salem H; Gallus A; Ferro V; McKinnon R;
    Intern Med J; 2014 May; 44(5):497-500. PubMed ID: 24816308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A world of low molecular weight heparins (LMWHs) enoxaparin as a promising moiety--a review.
    Ingle RG; Agarwal AS
    Carbohydr Polym; 2014 Jun; 106():148-53. PubMed ID: 24721062
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterization of currently marketed heparin products: key tests for LMWH quality assurance.
    Ye H; Toby TK; Sommers CD; Ghasriani H; Trehy ML; Ye W; Kolinski RE; Buhse LF; Al-Hakim A; Keire DA
    J Pharm Biomed Anal; 2013 Nov; 85():99-107. PubMed ID: 23917037
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low molecular weight heparins. An objective overview.
    Hoppensteadt D; Walenga JM; Fareed J
    Drugs Aging; 1992; 2(5):406-22. PubMed ID: 1327312
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Heparin monitoring: clinical outcome and practical approach.
    Despas N; Larock AS; Jacqmin H; Douxfils J; Chatelain B; Chatelain M; Mullier F
    Ann Biol Clin (Paris); 2016 Dec; 74(6):637-652. PubMed ID: 27848915
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Are the current guidelines for the acceptance of generic low molecular weight heparins adequate?
    Fareed J; Bick RL
    Clin Appl Thromb Hemost; 2003 Oct; 9(4):269-72. PubMed ID: 14653436
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.